<DOC>
	<DOC>NCT00348725</DOC>
	<brief_summary>The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.</brief_summary>
	<brief_title>Acceptability of a Fixed Combination of Fenofibrate and Metformin</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Patients with type 2 diabetes mellitus and dyslipidemia. Type 1 diabetes, uncontrolled type 2 diabetes, HbA1c â‰¥ 10 % Fasting plasma glucose &gt; 300 mg/dL Triglycerides &gt; 500 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Treatment of Dyslipidemia and of Type 2 Diabetes Mellitus</keyword>
</DOC>